{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360004235794584192.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1111/jvh.12691"}},{"identifier":{"@type":"URI","@value":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjvh.12691"}},{"identifier":{"@type":"URI","@value":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12691"}},{"identifier":{"@type":"PMID","@value":"28199034"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Hepatitis B surface antigen reduction by switching from long‐term nucleoside/nucleotide analogue administration to pegylated interferon"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Summary</jats:title><jats:p>Hepatitis B surface antigen (<jats:styled-content style=\"fixed-case\">HB</jats:styled-content>sAg) reduction during nucleoside/nucleotide analogue (<jats:styled-content style=\"fixed-case\">NA</jats:styled-content>) therapy is slow and an alternative strategy for patients receiving ongoing <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> to facilitate <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>sAg reduction is required. We investigated whether switching to pegylated interferon (<jats:styled-content style=\"fixed-case\">PEG</jats:styled-content>‐<jats:styled-content style=\"fixed-case\">IFN</jats:styled-content>) after long‐term <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> administration enhances <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>sAg reduction. Forty‐nine patients who switched from long‐term <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> to 48 weeks of <jats:styled-content style=\"fixed-case\">PEG</jats:styled-content>‐<jats:styled-content style=\"fixed-case\">IFN</jats:styled-content> alfa‐2a were studied. The mean duration of previous <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> was 48 months (sequential group). A total of 147 patients who continued <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> and matched for baseline characteristics were analysed for comparison (<jats:styled-content style=\"fixed-case\">NA</jats:styled-content> continuation group). The treatment response was defined as <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>sAg reduction ≥1.0 log<jats:styled-content style=\"fixed-case\">IU</jats:styled-content>/mL at the end of <jats:styled-content style=\"fixed-case\">PEG</jats:styled-content>‐<jats:styled-content style=\"fixed-case\">IFN</jats:styled-content>. <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>sAg reduction at week 48 was 0.81±1.1 log<jats:styled-content style=\"fixed-case\">IU</jats:styled-content>/mL in the sequential group, which was significantly higher than that in the <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> continuation group (0.11±0.3 log<jats:styled-content style=\"fixed-case\">IU</jats:styled-content>/mL, <jats:italic>P</jats:italic> < .001). The treatment response was achieved in 29% and 2% of the sequential group and <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> continuation group (<jats:italic>P</jats:italic> < .001), and the odds ratio of sequential therapy for the treatment response was 19 compared with the <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> continuation (<jats:italic>P</jats:italic> < .001). In patients tested positive for hepatitis B e antigen (<jats:styled-content style=\"fixed-case\">HB</jats:styled-content>eAg), <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>eAg seroconversion was higher in the sequential group (44% vs 8%, <jats:italic>P</jats:italic> < .001). In <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>eAg‐negative patients, only patients in the sequential group achieved <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>sAg loss. No patient needed to resume <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> administration because of <jats:styled-content style=\"fixed-case\">HBV DNA</jats:styled-content> increase accompanied by alanine aminotransferase flares. In summary, sequential therapy with <jats:styled-content style=\"fixed-case\">PEG</jats:styled-content>‐<jats:styled-content style=\"fixed-case\">IFN</jats:styled-content> after long‐term <jats:styled-content style=\"fixed-case\">NA</jats:styled-content> enhances the reduction of <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>sAg and may represent a treatment option to promote <jats:styled-content style=\"fixed-case\">HB</jats:styled-content>sAg loss.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004235794584195","@type":"Researcher","foaf:name":[{"@value":"N. Tamaki"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Musashino Red Cross Hospital  Tokyo Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584064","@type":"Researcher","foaf:name":[{"@value":"M. Kurosaki"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Musashino Red Cross Hospital  Tokyo Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584202","@type":"Researcher","foaf:name":[{"@value":"A. Kusakabe"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Japanese Red Cross Nagoya Daini Hospital  Nagoya Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584200","@type":"Researcher","foaf:name":[{"@value":"E. Orito"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Japanese Red Cross Nagoya Daini Hospital  Nagoya Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584204","@type":"Researcher","foaf:name":[{"@value":"K. Joko"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Matsuyama Red Cross Hospital  Matsuyama Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584207","@type":"Researcher","foaf:name":[{"@value":"Y. Kojima"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Ise Red Cross Hospital  Ise Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584320","@type":"Researcher","foaf:name":[{"@value":"H. Kimura"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Japanese Red Cross Kyoto Daiichi Hospital  Kyoto Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584192","@type":"Researcher","foaf:name":[{"@value":"Y. Uchida"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Matsue Red Cross Hospital  Matsue Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584206","@type":"Researcher","foaf:name":[{"@value":"C. Hasebe"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Asahikawa Red Cross Hospital  Asahikawa Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584065","@type":"Researcher","foaf:name":[{"@value":"Y. Asahina"}],"jpcoar:affiliationName":[{"@value":"Department of Hepatitis Control Tokyo Medical and Dental University  Tokyo Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380004235794584198","@type":"Researcher","foaf:name":[{"@value":"N. Izumi"}],"jpcoar:affiliationName":[{"@value":"Department of Gastroenterology and Hepatology Musashino Red Cross Hospital  Tokyo Japan"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13520504"},{"@type":"EISSN","@value":"13652893"}],"prism:publicationName":[{"@value":"Journal of Viral Hepatitis"}],"dc:publisher":[{"@value":"Wiley"}],"prism:publicationDate":"2017-03-20","prism:volume":"24","prism:number":"8","prism:startingPage":"672","prism:endingPage":"678"},"reviewed":"false","dc:rights":["http://onlinelibrary.wiley.com/termsAndConditions#vor"],"url":[{"@id":"https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjvh.12691"},{"@id":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jvh.12691"}],"createdAt":"2017-02-15","modifiedAt":"2023-10-02","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20Surface%20Antigens","dc:title":"Hepatitis B Surface Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Substitution","dc:title":"Drug Substitution"},{"@id":"https://cir.nii.ac.jp/all?q=Nucleotides","dc:title":"Nucleotides"},{"@id":"https://cir.nii.ac.jp/all?q=Interferon-alpha","dc:title":"Interferon-alpha"},{"@id":"https://cir.nii.ac.jp/all?q=Nucleosides","dc:title":"Nucleosides"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Antiviral%20Agents","dc:title":"Antiviral Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Recombinant%20Proteins","dc:title":"Recombinant Proteins"},{"@id":"https://cir.nii.ac.jp/all?q=Polyethylene%20Glycols","dc:title":"Polyethylene Glycols"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B,%20Chronic","dc:title":"Hepatitis B, Chronic"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Case-Control%20Studies","dc:title":"Case-Control Studies"},{"@id":"https://cir.nii.ac.jp/all?q=DNA,%20Viral","dc:title":"DNA, Viral"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Hepatitis%20B%20e%20Antigens","dc:title":"Hepatitis B e Antigens"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Retrospective%20Studies","dc:title":"Retrospective Studies"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040000781859646336","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"15K15285"},{"@type":"JGN","@value":"JP15K15285"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15K15285/"}],"notation":[{"@language":"ja","@value":"iPS細胞由来肝細胞系譜におけるHBV感染系の可視化とHBVを根絶する治療の創成"},{"@language":"en","@value":"Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus"}]},{"@id":"https://cir.nii.ac.jp/crid/1040000781900964352","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"16H05285"},{"@type":"JGN","@value":"JP16H05285"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-16H05285/"}],"notation":[{"@language":"ja","@value":"発癌・進展に関わる背景肝ゲノム要因の探索とiPS細胞を用いた肝発癌機構の統合解析"},{"@language":"en","@value":"Comprehensive analyses of gene mutational profile and viral integration in hepatocellular carcinoma and development of novel human iPS cells-derived disease model"}]},{"@id":"https://cir.nii.ac.jp/crid/1040000781975357696","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"17K19647"},{"@type":"JGN","@value":"JP17K19647"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-17K19647/"}],"notation":[{"@language":"ja","@value":"ヒトiPS細胞を用いた画期的人工発癌モデルの開発"},{"@language":"en","@value":"Development of human iPS cell-derived model for hepatocarcinogenesis"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360011145680524672","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Low pretreatment serum HBsAg level and viral mutations as predictors of response to PEG-interferon alpha-2b therapy in chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146253256832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292618685270656","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292619683510528","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With Adefovir"}]},{"@id":"https://cir.nii.ac.jp/crid/1360292621299941632","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168116348928","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"JSH Guidelines for the Management of Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1360574095786837760","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B # †"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848660687481088","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855568811805184","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sequential therapy with entecavir and <scp>PEG‐INF</scp> in patients affected by chronic hepatitis <scp>B</scp> and high levels of <scp>HBV‐DNA</scp> with non‐<scp>D</scp> genotypes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360855569222448896","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043540282496","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043631007872","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137044094805376","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Serum HBsAg Decline During Long-term Potent Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B and Prediction of HBsAg Loss"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046063566976","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418519126797952","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: Finite treatment duration unlikely"}]},{"@id":"https://cir.nii.ac.jp/crid/1361418521133119360","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Hepatitis B Virus Infection"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699996467003648","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470267574784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Entecavir Treatment for Up to 5 Years in Patients With Hepatitis B E Antigen–Positive Chronic Hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262944633938816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)"}]},{"@id":"https://cir.nii.ac.jp/crid/1362544418999024000","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: Two-year follow-up"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825894853927040","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Three Years of Continuous Entecavir Therapy in Treatment-Naïve Chronic Hepatitis B Patients: VIRAL Suppression, Viral Resistance, and Clinical Safety"}]},{"@id":"https://cir.nii.ac.jp/crid/1362825895734126592","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sequential Combination Therapy with Pegylated Interferon Leads to Loss of Hepatitis B Surface Antigen and Hepatitis B e Antigen (HBeAg) Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Entecavir Treatment"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670319523929728","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Serum HBsAg quantification to predict response to peginterferon therapy of e antigen positive chronic hepatitis B"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320413752832","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Long-term outcome of chronic hepatitis B in Caucasian patients: mortality after 25 years"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951794146051712","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Early on‐treatment prediction of response to peginterferon alfa‐2a for HBeAg‐negative chronic hepatitis B using HBsAg and HBV DNA levels†"}]},{"@id":"https://cir.nii.ac.jp/crid/1363951795546874368","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Sustained Immune Control in HBeAg-Positive Patients who Switched from Entecavir Therapy to Pegylated Interferon-α2a: 1 Year follow-up of the OSST Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233268838290816","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"<scp>HB</scp>sAg quantification to optimize treatment monitoring in chronic hepatitis B patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1364233269156808448","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"AASLD guidelines for treatment of chronic hepatitis B"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1111/jvh.12691"},{"@type":"KAKEN","@value":"PRODUCT-21104513"},{"@type":"KAKEN","@value":"PRODUCT-21751395"},{"@type":"KAKEN","@value":"PRODUCT-21518945"},{"@type":"OPENAIRE","@value":"doi_dedup___::ad78643508e3d46ca52b04c6e6ec50af"}]}